Prevention of mother-to-child Transmission: A report-back from the XV International AIDS Conference, Bangkok, 11 - 16 July 2004 by Martinson, Neil et al.
THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE                                            AUGUST 2004  17
The XV International AIDS Conference was held in Bangkok
from 11 to 16 July 2004. The theme of the conference was
‘Access for all’.  It was an enormous gathering; 10 000
abstracts were accepted for presentation, of which
approximately 400 were oral. There were 19 500 attendees
from all over the globe with a high representation from
Asian countries.   South Africa was well represented by a
large contingent including politicians, researchers, activists
and government officials. The abstracts and presentations
which may have an impact on policy and research
directions have been reviewed and are summarised. 
New World Health Organisation guidelines for the
prevention of mother-to-child transmission (PMTCT) of
HIV1 were presented at an evening satellite session. 
The guidelines, available at http://www.who.int/reproductive-
health/rtis/MTCT/, were compiled by a WHO-convened
Technical Consultation on Antiretroviral Drugs and the
Prevention of Mother-to-child Transmission of HIV
Infection in Resource-limited Settings in Geneva,
Switzerland in February 2004. The participants considered
the available scientific evidence and the programmatic
experience and recommended specific antiretroviral (ARV)
regimens according to different clinical situations. The
guidelines differ from the recommendations issued by
WHO in 2000, which focused mainly on the PMTCT of HIV,
by acknowledging the greater access to ARV treatment for
women and the desirability of providing ARV treatment for
women who need it. They complement other guidelines on
treatment issued by the WHO and the 3 by 5 Initiative.
Women may receive ARV drugs during pregnancy as part of
combination regimens used to treat their HIV infection or
to prevent HIV infection in infants. All efforts should be
made to ensure that access to ARV treatment for women is
based on their need and eligibility for such treatment.
However, ARV regimens for women of childbearing age
should be selected considering the possibility of a planned
or unintended pregnancy and that ARV drugs may be taken
in the first trimester of pregnancy, before a pregnancy is
recognised. While triple therapy is widely used in developed
countries to prevent HIV transmission in pregnancy, there
are concerns about its use for this indication in women
where clinical and laboratory monitoring is not readily
available.
The key recommendations from the new guidelines are: 
1. Women who need ARV treatment for their own health
should receive it in accordance with WHO guidelines on
ARV treatment. The use of ARV treatment, when indicated,
during pregnancy substantially benefits the health of the
woman and decreases the risk of HIV transmission to the
infant.
2. HIV-infected pregnant women who do not have
indications for ARV treatment or do not have access to
treatment should be offered ARV prophylaxis to prevent
MTCT using one of several ARV regimens known to be safe
and effective:
■ Zidovudine (AZT) from 28 weeks of pregnancy plus
single-dose nevirapine (NVP) during labour and single-
dose NVP and 1-week AZT for the infant. This regimen
is highly efficacious, as is initiating AZT later in
pregnancy.
■ Alternative regimens based on AZT alone, short-course
AZT + lamivudine (3TC) or single-dose NVP (sdNVP)
alone are also recommended.
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Non-nucleoside reverse transcriptase inhibitor (NNRTI)
resistance was a focus of this conference.  Specifically the
resistance induced by sdNVP to both pregnant mother and
the newborn infant attracted much attention.  The
predominant research method of assessing resistance is to
analyse for the presence of viral DNA mutations that are
known to confer resistance to specific ARV drugs. The
presence of detectable genotypic resistance was reported
in three cohorts of women and children.  A study of
mother-infant pairs recruited from the PMTCT programme
in Soweto and Durban who were exposed to single-dose
NVP in 2002-2003 was presented.2 Previous data from this
study showed that 40% of women and 45% of children
were found to have genotypic resistance to NNRTIs  at 7
weeks after delivery.3 The paper presented at Bangkok
reported the fading of genotypic NNRTI resistance to 6
months after the dose of NVP in both mothers and
children, and reported the pattern of resistant mutations
found. Figs 1 and 2 below show levels of detectable
resistance found prior to the NVP dose in pregnant
mothers, at 7 weeks after delivery and at 6 months after
delivery, respectively. Ninety-eight per cent of the women
were infected with clade C HIV.
This study confirmed previous work showing that not only
do detectable resistant mutations fade but also the
diversity of the mutations diminishes.
A similar study of NVP-induced genotypic resistance in
Thailand assessed the pattern of NNRTI-resistant
mutations in a population where the predominant HIV
subtype is CRF01_AE.3 Three hundred and ten women with
advanced disease who received sdNVP had genotypic
resistance assays performed 10 days and 6 weeks after
delivery.  Overall, the data reported were similar to the work
done in South Africa on clade C viruses.3 NNRTI mutations
were found in 38% of the women exposed to sdNVP.4
Seventy-three per cent of the women with resistance had
single-mutation resistance and 27% had at least two
mutations. The most common mutation in this study, as in
the South African work reported previously, was K103N
(65%).  However, the second most frequent maternal
resistance mutation was G109A (30%), an infrequent
mutation in the South African series.
A potential strategy to reduce maternal NNRTI resistance is
to not expose the mother to NVP at all.  A randomised open
label clinical trial was presented that tested two
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interventions to prevent transmission of HIV in infants
whose HIV-infected mothers were not able to access
antenatal ARVs in PMTCT programmes.5 This trial, which
recruited 1 051 infants, was undertaken at the Perinatal HIV
Research Unit at Chris Hani Baragwanath Hospital.  It
compared HIV transmission rates in infants whose mothers
did not receive ARVs to prevent MTCT for a variety of
reasons. Infants were randomised to receive either: 
1. A single dose of NVP (2 mg/kg within 72 hours of
delivery) or 
2. A  6-week course  of twice daily AZT commenced within
24 hours of delivery.  
Transmission for the entire group at 12 weeks was 16.3%
and transmission in the intention-to-treat analysis is
shown in Table I.  
Overall, sdNVP was better at reducing transmission than 6
weeks of AZT in this group of infants of mothers who had
not accessed an antenatal PMTCT programme.
Furthermore, the burden on the health service is markedly
reduced by giving a stat post-partum dose compared with
ensuring that 6 weeks of AZT are provided and ingested by
a newborn. An oral paper reported the genotypic resistance
induced by the sdNVP arm in this study.6 Only 3 of 23 HIV-
infected infants whose mothers did not receive NVP and
who were randomised to the sdNVP arm were found to
have genotypic resistance compared with approximately
45% of infants exposed to maternal NVP in utero and then
themselves receiving sdNVP after delivery. The patterns of
resistance also differed, with those exposed to only their
own sdNVP dose having fewer mutations than those
exposed to additional maternal sdNVP as part of HIVNET
012 regimen.
The resistance generated by sdNVP may in part be due to its
long half-life.  A paper presented by a combined Thai/US
group showed NVP plasma levels in 61 women who had
recently taken sdNVP to prevent MTCT. Although plasma
exposure and Cmax were found to be significantly less in
pregnant women than in non-pregnant women and men,8
NVP was detected in women who had delivered up to 21
days post partum,7 albeit at low concentrations. The median
half-life of NVP was 58.3 hours in this study.7
The implications of detection of genotypic resistance are
uncertain. However, there is recently published evidence
that genotypic resistance induced by sdNVP and exposure
to sdNVP without the presence of detectable resistance
compromises viral response to triple therapy.9 It is
generally agreed that where possible resistance should be
minimised.  One way of doing this is to avoid NVP
altogether.  An alternative approach presented at the
conference is to provide a short course of Combivir, started
simultaneously with maternal sdNVP to cover the ‘tail’ of
the prolonged NVP plasma half-life.10 A study sponsored by
Boehringer-Ingelheim, the manufacturers of NVP, and
undertaken in South African hospital settings tested the
hypothesis that the addition of intrapartum and
postpartum Combivir (a fixed dose combination of AZT and
3TC) would reduce maternal NNRTI resistance.   Preliminary
results of this randomised open-label trial (Table II)
providing Combivir post sdNVP to reduce resistance
suggest that it is effective in reducing maternal genotypic
resistance when compared to sdNVP alone.
Owing to the marked reduction of genotypic resistance in
the two Combivir-containing arms, the trial was amended
and randomisation to the sdNVP-only arm was stopped.
The trial will continue to enrol pregnant women into the
two Combivir-containing arms in an attempt to determine
the better duration of Combivir cover.   
NVP, resistance induced by sdNVP and the ongoing
interactions between activists, the South African Medicines
Control Council and researchers dominated the news
reporting of this conference both in South Africa and
internationally.  The precipitant for this was a media release
emanating from the MCC headlined ‘MCC no longer
recommends the use of monotherapy in preventing mother
to child transmission’.11 This was interpreted as a signal of
the imminent deregistration of NVP as monotherapy in
South Africa for MTCT, and created concern that the PMTCT
programme in South Africa was in jeopardy. The Treatment
Action Campaign (TAC) then convened a meeting where a
PREVENTION OF RESISTANCE
Arm Birth 6 weeks 12 weeks
sdNVP 7 11.9 14.3
6 weeks AZT 5.8 13.5 18.1
p 0.5 0.6 0.4
TABLE I. TRANSMISSION RATES BY ARM AND TIMING OF
INFANT HIV PCR TEST5
Presence of resistance (%)
Arm 2 weeks 6 weeks
sdNVP 9/18 (50) 9/18   (50)
sdNVP, 120 (5)
Combivir 4 days 4/43   (10)
sdNVP, 3/23 (13)
Combivir 7 days
TABLE II. MATERNAL RESISTANCE BY TREATMENT ARM9
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joint press statement from UNAIDS, UNICEF and the
Elizabeth Glazer Paediatric AIDS Foundation was read.12
This meeting was also addressed by representatives of TAC,
Médecins Sans Frontières and the UN Secretary General’s
special envoy for HIV/AIDS in Africa, Stephen Lewis, who
expressed concern that yet another South African NVP spat
was diverting attention away from more serious issues of
the HIV epidemic.   A day later, when the registrar of the
MCC clarified the MCC position it became clear that
deregistration of NVP was not imminent.  Whether this was
despite or as a result of the TAC, UN and EGPAF action was
unclear.  
The impact of maternal AZT on fetal and infant growth in 
1 265 infants was assessed in Thailand.13 After adjusting
for a variety of potential confounders, the researchers
reported that the duration of maternal AZT was statistically
significantly associated with increased weight and height
at birth.  This association persisted for up to 18 months of
age, independent of gestational age at birth. Maternal AZT
was started at 28 or 35 weeks’ gestation and babies
received either 3 days or 6 weeks of AZT after delivery.  
However, the use of ARVs is not without risk.  A single case
report14 from the US of an  HIV-uninfected baby with
extreme hypotonia whose mother was treated with AZT-
containing HAART and who was given 6 weeks of AZT after
delivery provides isolated evidence of potential toxicity of
ARVs. Muscle biopsy showed mitochondrial abnormalities
that were attributed to NRTIs.
Rapid testing is gaining acceptability and is of great value
in the antenatal clinic where one visit may be the only
contact a pregnant woman has with the health service
before delivery.  A report from Lilongwe15 confirmed the
powerful effect of an immediate HIV result on uptake of
VCT.  This group compared the acceptance of HIV testing
and the rate of attendance at post-test counselling in two
groups:
1. Pregnant women who were HIV tested using an HIV-
ELISA with results obtainable some days later. 
2. Women who were able to access a rapid testing
algorithm with same-day results. 
They used the periods before and after the introduction of
rapid testing as comparison periods. The results are
summarised in Table III.  
In another report from Kigali, Rwanda,16 where rapid tests,
infant formula and NVP have been made available in the
PMTCT programme, 98% of pregnant women accepted a
rapid HIV test of whom 79% attended a post-test
counselling session.  Of the 21% found to be HIV-infected,
91% took NVP.  Notwithstanding the simplicity of the NVP-
based PMTCT regimen, an abstract from Malawi17 showed
that despite high uptake of VCT less than half the HIV-
infected women in  their programme were handed a tablet
of NVP by 36 weeks of gestation and only 34% of the
newborns of HIV-infected mothers received a dose of NVP. 
In keeping with the theme of ‘Access for all’, it was
gratifying to note the large number of abstracts that
summarised the experiences of numerous PMTCT
programmes documenting the cascade.   Several abstracts
from throughout Africa reported on the drop-off in the
PMTCT cascade from acceptance of counselling to maternal
receipt of NVP. All of them reported rates of maternal HIV-
infection of greater than 15%.
Few data were presented on the effectiveness of PMTCT
programmes in preventing HIV transmission when
implemented on a large scale.   A multi-centre collaborative
study from Brazil,18 where AVRs are  provided free of charge
to HIV-infected people, reports data from 63 sites in Brazil
for the years 2000 - 2002.  The overall MTCT rate of HIV was
6.8%.  Ninety-two per cent of the infants received AZT.
Higher rates of transmission were reported in women who
breast-fed, had a vaginal delivery, and  took ARVs
incorrectly. 
These summarised abstracts represent the papers on MTCT
which we believe had the most impact at the conference.
Further work on infant feeding and programmatic
experiences added to the knowledge base. A searchable
archive of all abstracts presented at the Conference (eJIAS
abstract finder) is available at http://www.aids2004.org/.
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